Multiplexed Peptide Core for Autoantigen Antibody Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for efficiently producing antibodies, particularly against autoantigens and emerging pathogens, are limited by T cell recognition restrictions and require complex antigen preparation and adjuvant administration.
Innovation Solution
A multiplexed same type-antigenic peptide comprising a dendritic core and B-cell recognition peptides, which directly stimulates B cells in vivo without requiring T cell epitopes, thereby inducing class-switched antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antigen preparation methods are used, then antibodies can be produced against foreign pathogens, but the method fails to produce antibodies against autoantigens due to T cell restriction
Solution Approach 1:
The invention segments the antigen into multiple identical peptide copies (4-12 copies) arranged in a dendritic structure. This segmentation allows the antigen to be recognized by B cells through direct binding to the peptide array, bypassing the need for T cell recognition and processing. The segmented structure presents multiple identical epitopes that can simultaneously engage multiple B cell receptors, enabling robust antibody production against autoantigens that were previously inaccessible due to T cell restriction.
Solution Approach 2:
The dendritic peptide structure acts as an intermediary that facilitates direct B cell activation without requiring T cell mediation. The structured array of peptide copies serves as a bridge between the antigen and B cell receptor, enabling direct recognition and activation. This intermediary structure overcomes the limitation of T cell restriction by providing an alternative activation pathway that does not depend on T cell epitope recognition.
2Productivity
If adjuvants are administered to force T cell recognition, then antibody production is enhanced, but the process becomes more complex and requires additional substances
Solution Approach 1:
The invention extracts and eliminates the requirement for adjuvants and T cell epitopes from the immunization system. By designing a dendritic structure with multiple identical peptide copies, the invention achieves effective B cell activation without needing adjuvants to force T cell recognition. The structured peptide array itself provides sufficient signal for B cell activation, simplifying the immunization system by removing unnecessary components.
Solution Approach 2:
The dendritic peptide structure is self-sufficient in activating B cells without requiring external adjuvants or T cell help. The multivalent presentation of identical epitopes on the dendritic core provides intrinsic activation signals that are sufficient to drive antibody production. This self-service capability eliminates the need for additional adjuvant substances and reduces system complexity.
3Quantity of substance
If mass culture systems are established for pathogen antigens, then vaccines can be produced, but it takes many years to establish the system and cannot keep up with rapid pathogen mutations
Solution Approach 1:
The invention uses synthetic peptide copying instead of biological pathogen culture. Identical peptide sequences are synthesized chemically and arranged in dendritic structures, creating exact copies of the antigenic epitopes without needing to culture the actual pathogen. This copying approach allows rapid production of vaccine antigens that can be easily updated to match pathogen mutations, eliminating the years-long delay associated with establishing and adapting mass culture systems.
Solution Approach 2:
The invention changes the production parameter from biological culture to chemical synthesis. By using synthetic peptide chemistry rather than pathogen culture, the system achieves rapid antigen production that can be quickly adjusted to match evolving pathogen sequences. This parameter change from biological to chemical production enables timely response to pathogen mutations while maintaining sufficient antigen quantity for vaccine development.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide comprising a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent comprising the peptides; and a method for producing the peptide.